Message from Dr. Hollenberg – New Chair of Medicine

As Chair of the Department of Medicine I look forward to our journey ahead. While the Covid-19 pandemic has changed and will continue to change medicine our Department will remain committed to its missions including: A. outstanding and equal care for all; B. health equity; C. research that spans all domains from the laboratory bench to local and global health and D. educational programs that position the next generation for success.

We remain indebted to our history as a Department and the outstanding achievements of our faculty and staff. Now with close to 500 faculty, 14 Sections 15 research centers we are poised to broaden and expand our excellence. Our location in Boston provides the ideal backdrop to care for our community and to expand our basic, translational and clinical research programs.

Home to one of the country’s leading residency programs our Department is able to provide outstanding clinical and research opportunities to our housestaff, fellows-in training and medical students. Our faculty provide outstanding and diverse mentorship to our trainees allowing them to succeed both in their field of choice and type of career they seek whether it be clinically focused or as a physician-scientist.

We appreciate your interest and hope you will contact us if we can provide any additional information about Boston University’s Department of Medicine.

Goals of the Department of Medicine

We believe that our success as a department is dependent upon exceptional achievement in each of our core missions of research, clinical care, and education.

In order to continue our leadership role as one of the country’s leading research-intensive Departments of Medicine, we expect to:

  • Expect, support and reward both high aspiration and exceptional achievement;
  • Vigorously support a departmental community characterized by curiosity; collegiality, openness, mutual respect, diversity, integrity, generosity, and  service;
  • Provide sustained and meaningful mentorship;
  • Seek continuously higher achievement relative to historical and external benchmarks with a particular aversion to complacency;
  • Be attentive to the special obligation and honor in providing exemplary care for all members of the community, especially our underserved patient population;
  • Create discoveries that inspire our peers, establish new paradigms for future discovery, and ultimately improve the health of individuals and populations of patients;
  • Establish and continuously refine new models for achieving excellence by working across disciplines in our research, education, and clinical programs;
  • Develop responsive, supportive and challenging educational programs that enable our trainees and faculty to acquire outstanding, broad-based competencies;
  • Create policies and operations characterized by effectiveness, efficiency, integrity, equity, responsiveness, and value to patients, internal stakeholders, regulatory agencies and our institutional affiliates.

Ultimately, we seek to be a department that leads through the impact of our work, the generosity of our actions, the example we provide, and the value we bring to our profession and to the public.

Anthony Hollenberg, M.D.
John Wade Professor and Chairman, Department of Medicine

Welcome Dr. Hollenberg – Chair of the Department of Medicine!

We are pleased to announce that Anthony “Tony” Hollenberg, MD, has been named the John Wade Professor and Chair of the Department of Medicine (DOM) at Boston University School of Medicine (BUSM), and Physician-in-Chief at Boston Medical Center (BMC). Dr. Hollenberg joins BUSM/BMC Monday, November 14th(today!).

Currently, Dr. Hollenberg is the Chair of the Joan and Sanford I. Weill Department of Medicine at Weill Cornell Medicine and Physician-in-Chief at New York-Presbyterian/Weill Cornell Medical Center in New York City. Prior to this role, he served as Chief of the Division of Endocrinology, Diabetes, and Metabolism and Vice Chair for Mentoring at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School.

Dr. Hollenberg, a native of Toronto, received his bachelor’s degree from Harvard College and his medical degree from the University of Calgary. He completed his residency in Internal Medicine at Beth Israel Deaconess Medical Center, followed by a clinical and research fellowship at Massachusetts General Hospital.

A leading physician-scientist specializing in endocrinology, Dr. Hollenberg’s work focuses on thyroid disorders, investigating the physiological and molecular mechanisms by which thyroid hormones regulate metabolism, including body weight. Additionally, his laboratory explores the underpinnings of thyroid gland development. He has published more than 98 original studies in journals and contributed 31 book chapters and reviews. Dr. Hollenberg’s extensive research expertise will enhance pre-clinical, translational, and clinical research across the Department.

Under his leadership, the Department will cultivate and attract top talent in academic medicine and research while also fostering and mentoring emerging talent, advancing our core missions, and raising BUSM/BMC’s national profile even further.

We thank David Coleman, MD, who has served as Chief and Chair of the Department of Medicine since 2006, who announced his plans last year to step down from his leadership role. We are grateful for Dr. Coleman’s many lasting contributions to the Department, including the recruitment of outstanding faculty and growing the Department’s research programs in size and scope, and for his exceptional leadership and his many contributions to our health system, faculty practice, medical school, and professional community over his 16 years at BUSM/BMC.

We also would like to thank Jennifer Tseng, MD, MPH, Chief and Chair of Surgery, and Sandro Galea, MD, MPH, DPH, Dean and Robert A. Knox Professor, Boston University School of Public Health, who led the search committee, as well as the committee members for their work that developed a very strong national candidate pool.

Please join us in thanking Dr. Coleman and welcoming Dr. Hollenberg back to Boston.

Congratulations to the 2022 Evans Days Winners!!!!!!!!

Evans Days Poster & Presentation Winners

Clinical Poster Winners:

1st Place - Dylan Steiner
2nd Place - Najia Idress
3rd Place - Divya Shankar, MD

Basic Science Poster Winners:

1st Place - Liang (Martin) Ma, MD, PhD Candidate
2nd Place - Anna McGregor
3rd Place -  Mehmed Taha Dinc, MD

Clinical Oral Presentation Winners:

1st Place - Ioanna Yiannakou, RDC, MS, PhD Candidate
2nd Place - Samantha Siskind, MD
3rd Place - Ross Okazaki

Basic Oral Science Presentation Winners:

1st Place - Kiloni Quiles
2nd Place - David Bean
3rd Place - Fatima Rizvi, PhD

Faculty Award Winners

Outstanding Citizenship Award

Frederick Ruberg, MD - Cardiovascular Medicine

Clinical Quality Improvement Award

Nicholas Bosch, MD, MSc - Pulmonary, Allery, Sleep & Critcal Care

Clinical Innovation Award

Pablo Buitron de la Vega, MD, MSc - General Internal Medicine

Junior Faculty Mentoring Award

Deepa Gopal, MD, MS - Cardiovascular Medicine

Excellence in Education Scholarship Mentoring Award

Lindsay Demers, MS, PhD - Geriatrics

Research Mentoring Award

Renda Wiener, MD, MPH - Pulmonary, Allergy & Critical Care

Special Recognition Teaching Award

Ashish Upadhyay, MD - Nephrology

Clinical Excellence Award

Ramon Bonegio, MD - Nephrology

Faculty Diversity Award

Elizabeth Klings, MD - Pulmonary, Allergy, Sleep & Critical Care

Evans Clinician

Ashvin Pande, MD - Cardio Vascular Medicine
Christine Reardon, MD - Pulmonary, Allergy, Sleep & Critical Care
Michael York, MD - Rheumatology
Sandhya Rao, MD - General Internal Medicine

 

Staff Awards Winners

Maria Antoinette Evans Award

Inel Ferrara - Hematology & Oncology
Amanda Tran, MPH - Geriatrics

David "Aaron" Freed Award

Jennifer Fosbroke - General Internal Medicine

 

Evans Center/IBRO

Outstanding Research Collaborator Award

David Sherr, MD - Environmental Health

 

 

 

Evans Day Poster Session Schedule is now Live!!!

2022 Evans Day Poster Session
Thursday, October 13, 9:30 AM - 12:45 PM
Hiebert Lounge

Trainee Poster Display Schedule

To see when and where trainee research is being presented CLICK HERE

Faculty Poster Display Schedule

This year, because of the unprecedented number of submissions and space limitations in the Hiebert Lounge, we have to deviate slightly from the normal process. We have designated 2 e-poster boards as Faculty poster boards and will be assigning each faculty member a 20 minute slot of time during one of the poster sessions in which their posters will be displayed. See the schedule of faculty posters below:

Basic Science Poster Session 1: 9:30 AM - 11:00 AM

Board #61

9:30 AM - 9:50 AM: Liying Xue - Vasular Biology - "Heteroplasmic Mitochondrial Genetic Variation in the Human Heart"

9:55 AM - 10:15 AM: Karan Smith - Vascular Biology - "Association of Mitochondrial Genetic Variation with Oxidative Phosphorylation Complex Activities"

10:20 AM - 10:40 AM: Kim Vanuytsel - CReM - "Multi-modal Profiling of Human Fetal Liver Hematopoietic Stem Cells Reveals the Molecular Signature of Engraftment"

10:30 AM - 10:50 AM: Joseph Kaserman - CReM - "Modeling ZAAT-Driven Gain-of-Function Toxicity in MZ Heterozygous Patient iPSC-Derivatives"

Board #62

9:30 AM - 9:50 AM: Sudhir Kumar - Nephrology - "Therapeutic Blockade of the SLIT/ROBO Signaling Pathway Alleviates Podocytopathy Defects in ILK Podocyte-Specific Knockout Mice"

9:55 AM - 10:15 AM:  Enkhjargal Budbazar - Vascular Biology - "Reversibly Oxidized SIRT1 Downregulates TIMP1 in Aortic Aneurysm of Marfan's Syndrome"

10:20 AM - 10:40: Saravanan Subramaniam - Pulmonary - "Proteomic and Phosphoproteomic Analyses Reveal Hyperactive Phenotype of Platelets in Humanized K18-ACE2 Mice Infected with SARS-CoV-2"

 

Clinical & Basic Poster Session 2: 11:15 AM - 12:45 PM

Board #61

11:15 AM - 11:35: Insa Schmidt - Nephrology - "Patients’ Perspectives on Race and the Use of Race-Based Algorithms in Clinical Decision-Making: A Qualitative Study"

11:40 AM - 12:00 PM: Sonia Ananthakrishnan - Endocrinology - "Opening the Pandora’s box of “Confidence” in Feedback" 

12:05 PM - 12:25 PM: Titilayo Ilori - Nephrology - "Urinary Sodium, Potassium and Kidney Function: Cross-sectional Analyses from African and US CKD Cohorts"

12:30 PM - 12:50 PM: Adrian Ilinski - Hematology & Oncology - "Prospective Breast Biopsy Collection at an Urban Safety-Net Hospital Serving a Diverse Patient Population"

Board #62

11:15 AM - 11:35 AM: Devin Steenkamp - Endocrinology - "Glucose Data Analytics: A Precision Medicine Strategy to Identify Diabetes Subtypes. Proof-of-Concept Application to Differentiate between HNF1A Diabetes (MODY3) and Type 1 Diabetes"

11:40 AM - 12:00 PM: Mark Dodge - CReM - "Alpha-1 Antitrypsin Deficiency Adult Clinical and Genetic Linkage Study"

12:05 PM - 12:25 PM: Priya Gajjar - Cardiology - "Physiological and Clinical Correlates of Exercise Blood Pressure Responses in the Community"

12:30 PM - 12:50 PM: Justin Battaglini - Hematology & Oncology - "Disparities in Response to Immunotherapy in those Diagnosed with Hepatocellular Carcinoma: A Retrospective Chart Review"

 

BUMC Faculty Promotions – June 2022

Associate Professor

 

Joshua Campbell, PhD, BUSM, Medicine/Computational Biomedicine, has established his lab as one of the leading computational genomics groups developing novel algorithms and software to address unmet needs across a variety of cancers. His group has developed novel statistical methods to identify transcriptional modules in single-cell RNA-seq data and mutational signatures in cancer genomic data, which has led to R21, R01 and U01 funding in collaboration with several other groups across the University. Dr. Campbell serves as the co-director of the department of medicine’s Single Cell Core, which provides data analysis services for investigators with single-cell data. Within the NCI’s Human Tumor Atlas Network (HTAN), he is contributing to the Lung Pre-Cancer Atlas and identifying molecular alterations that are responsible for initiation and progression of lung premalignant lesions. He leads a cross-center HTAN working group to develop data standards for single-cell RNA-seq that can be used by the research community. His translational research also includes characterization of prostate cancer where he is identifying mutational events and cell states that may contribute to disparities in outcomes in African American populations.

 

Naomi Y. Ko, MD, MPH, AM, BUSM, Medicine/Hematology & Oncology, specializes in breast cancer clinical care and research, with a particular focus on cancer disparities, and is the co-Director of the breast cancer program at Boston Medical Center (BMC). Dr. Ko’s research includes health services, translational, and epidemiological studies, all focused on health equity. Most notably, Dr. Ko recently received an R01 grant as co-PI to study disparities in triple negative breast cancer. Over the years she has received funding both as principal investigator and co-investigator, playing a key role as BMC’s site lead investigator on numerous grants, as well as several cancer clinical trials. She is known nationally for her dedication to equity and frequently invited to speak on the complexity of breast cancer disparities. Dr. Ko is also the recipient of several clinical excellence awards, including the national Arnold P. Gold Humanism in Medicine award.

 

Karsten Lunze, MD, MPH, DrPH, BUSM, Medicine/General Internal Medicine, is a global health expert who has pioneered evidence-based, behavioral interventions to help people with HIV, addictions and other socially disadvantaged conditions cope with stigma as a barrier to quality care. He co-directs the Boston-Providence CFAR Substance Use Research Core and is a teacher and mentor to many graduate students, postdoctoral fellows and early-career faculty. Dr. Lunze applies rigorous quantitative, qualitative and mixed methods in clinical sciences and population health. His research has used a broad methodological spectrum to optimize clinical processes and thus population health, including pharmacological and behavioral intervention studies of various designs, clinical health services research, implementation science, policy and human rights analyses, program evaluations, ethical analyses and more. In partnerships with communities of people with lived experiences and civil society organizations in Eastern Europe, Central and Southeast Asia, he has geographically and methodologically extended BU’s existing expertise and global networks to better serve vulnerable populations worldwide.

 

Clinical Associate Professor

Alan Malabanan, MD, BUSM, Medicine/Endocrinology, is a clinician educator who specializes in metabolic bone diseases and osteoporosis. He was recruited back to BMC/BUSM in 2021 to serve as director of the Bone Health Clinic, including oversight of the Bone Density Program. In these roles, he will restructure the clinical and educational programs in bone disorders, including developing service lines with orthopedics, geriatrics and rheumatology. He also will serve as section quality director,  as well as the quality projects of second-year fellows.

DoM Faculty Promotions – May 2022

Congratulations to the following faculty on their recent appointment or promotion.

Professor

Elizabeth Klings, MD, BUSM, Medicine/Pulmonary/Critical Care, is an adult pulmonary/critical care physician and clinician investigator who has a unique career niche in pulmonary hypertension (PH) of sickle cell disease (SCD). She has built a portfolio of publications, committee work and invited lectures, which has led this field for more than a decade. Dr. Klings directs the largest sickle cell center in New England. She has fundamentally shifted the care of patients through creation of unique clinical programs focused on providing multi-disciplinary comprehensive care. Dr. Klings has expanded the education program for trainees and formalized expansion of the clinical trials program. Her work contributed to the early recognition of patients with SCD being at increased risk for severe COVID-19 by the CDC. While her role internationally in sickle cell lung disease is clear, it is important to note her contributions to the field of pulmonary hypertension (PH). In 2018, Dr. Klings became Director of the PH Center at BU/BMC. Clinically, she created a program that incorporates junior faculty and specialized PH training for pulmonary/critical care fellows. The PH research program now consists of four faculty members within pulmonary along with collaborators in cardiology and rheumatology.

 

Associate Professor 

Vijaya Kolachalama, PhD, BUSM, Medicine/Computational Biomedicine, is a founding member of BU’s Faculty of Computing & Data Sciences and affiliated with the department of computer science. Research interests of his group currently lie at the interface of machine vision, representation learning and domain generalization. His laboratory has spent a significant amount of time to develop automated frameworks to tackle big datasets from multiple cohorts containing tens of thousands of patient samples. He brings multidisciplinary talent from both Charles River and Medical campuses, thereby enabling machine learning-driven innovation along with pursuing clinically relevant questions that have translational significance. His laboratory is funded by multiple awards from the National Institutes of Health, American Heart Association, private foundations and the pharmaceutical industry. His course, Machine Learning for Biomedical Applications, attracts a diverse set of individuals with little to no background in computer science.

Giovanni Ligresti, PhD, BUSM, Medicine/Rheumatology, leads a successful NIH-funded research program on pulmonary fibrosis. He studies epigenetic and transcriptional mechanisms regulating vessel remodeling and myofibroblast differentiation during lung scarring. Dr. Ligresti’s work has led to the discovery that epigenetic repression of metabolic genes is critical to promote lung fibroblast activation in response to biochemical and biomechanical stimuli, laying the groundwork for the development of novel therapeutic strategies to block epigenetic gene repression to reverse lung fibrosis. In addition, his research team is also interested in studying the contribution of aging to lung vascular dysfunction, disrepair, and persistent lung fibrosis.

Xiaoling Zhang, MD, PhD, BUSM, Medicine/Biomedical Genetics and Biostatistics, is a bioinformatician with more than 10 years of research experience combining clinical, genetics, and functional genomics to identify genes, biomarkers and molecular mechanisms for human complex diseases including smoking-related lung diseases, cardiovascular diseases and Alzheimer’s disease (AD). Dr. Zhang plays a leadership role in core analysis groups for the Alzheimer’s Disease Sequence Project (ADSP) and the AD Genetics Consortium. In addition, she leads the RNA-Seq harmonization effort within the Functional Data Harmonization Core of the NIA-funded Genome Center for Alzheimer’s Disease, and mitochondrial DNA and functional genomics projects for the ADSP. Dr. Zhang is an executive committee member of the newly formed ADSP-Functional Genomics Consortium, in which she received as contact-PI a $3.6M U01 to identify circular-RNAs and their interactions with RNA-binding proteins to modulate AD-related neuropathology. More recently she has been co-leading a $2.4M U19 (Project 2) to establish the Framingham Heart Study Brain Aging Program.

 

Clinical Associate Professor

Craig Noronha, MD (MED'03, CAS'99), BUSM, Medicine/GIM, is a clinician-educator and advocate for effective use of information technology (IT). He splits his clinical time between outpatient primary care and inpatient medicine, the latter at both Boston Medical Center (BMC) and the West Roxbury VA Hospital. He has been an integral part of BMC IT planning, implementation and optimization over the last 15 years. Dr. Noronha has served as an associate program director (APD) for the Internal Medicine Residency Program since 2011. In his role as an APD, he directs residency quality Improvement and career development programs and curricula. He has led dozens of educational workshops at both the local and national level. Dr. Noronha’s educational focuses include feedback in medical education, residency scheduling models, and high-value care.

Catherine Rich, MD, BUSM, Medicine/General Internal Medicine, is a general internist and clinician-educator focused on training primary care physician leaders for urban underserved populations. Since 2011 she has led the Primary Care Training Program within Boston Medical Center’s (BMC) Internal Medicine Residency. Under her leadership, the program has recruited, trained and graduated more than 55 residents who are thriving in ambulatory careers. Through her leadership, focus on building inclusive learning environments, and innovative programming around care of marginalized populations, she has impacted the development of the primary care workforce at BMC and across the nation. She was the recipient of the prestigious Society of General Internal Medicine New England Regional Award for Excellence as a Clinician Educator in 2020, an award given annually to a physician faculty member from among the medical institutions in the northeastern U.S.

Ad Interim Leadership for the Framingham Heart Study

Joanne Murabito, MD, and George O’Connor, MD, have agreed to serve as ad interim directors and co-principal investigators of the Framingham Heart Study (FHS), effective 9/1/2022, replacing Vasan Ramachandran, MD, who will be leaving BU in September to become the founding Dean of the University of Texas School of Public Health at San Antonio. We are planning a national search for a permanent director and PI in partnership with the NHLBI.

Dr. Murabito studies the determinants of healthy aging and longevity and reproductive aging in the community, as well as genetic and genomic factors. Dr. Murabito is also introducing mobile health into the FHS and exploring the use of mHealth in older adults to improve health and function. She leads multidisciplinary international consortia including the Cohorts for Heart and Aging Research in Genomics Epidemiology (CHARGE) and the Aging and Longevity working group. 

Dr. O’Connor studies genome-wide associations at the FHS seeking novel genetic determinants of lung function impairment, interstitial lung abnormalities and atopy. He has been the BU site PI of many NIH-funded, multi-center studies, including the Inner-City Asthma Consortium (ICAC), the Vitamin D Antenatal Asthma Reduction Trial (VDAART), and the All of Us Research Program.

George O’Connor, M.D., M.S. – Interim Chief of the Section of Preventive Medicine in the Department of Medicine

We are delighted to announce that George O’Connor, M.D., M.S. has agreed to serve as Interim Chief of the Section of Preventive Medicine in the Department of Medicine starting September 1, 2022. Dr. O’Connor is Professor of Medicine based in the Pulmonary Section. He is internationally known for his studies of the epidemiology of chronic respiratory diseases, particularly in asthma, and currently serves as Associate Editor of JAMA. Dr. O’Connor is also a skilled clinician and educator, in addition to his considerable accomplishments as a physician investigator.

 

Dr. O’Connor will be replacing Dr. Vasan Ramachandran who will be moving to the University of Texas at San Antonio to become the founding Dean of the School of Public Health. Dr. Ramachandran is one of the world’s leading cardiovascular epidemiologists who has led a number research and training programs in the Department and School of Medicine, especially including the Framingham Heart Study and RURAL study, two of the most important longitudinal studies of cardiovascular risk in the U.S. We are very grateful for his academic leadership, mentorship of innumerable trainees and faculty, and his enduring positive impact on the Department.

 

Please join us in congratulating Dr. O’Connor and in thanking Dr. Ramachandran for his leadership!